SFERA Archivio dei prodotti della Ricerca dell'Università di Ferrara

CIANCETTA, Antonella
 Distribuzione geografica
Salva come PNG Salva come JPEG
Continente #
NA - Nord America 3.163
AS - Asia 1.603
EU - Europa 677
SA - Sud America 386
AF - Africa 29
OC - Oceania 5
Continente sconosciuto - Info sul continente non disponibili 1
Totale 5.864
Salva come PNG Salva come JPEG
Nazione #
US - Stati Uniti d'America 3.098
SG - Singapore 738
CN - Cina 366
BR - Brasile 326
IT - Italia 203
HK - Hong Kong 186
VN - Vietnam 119
DE - Germania 98
GB - Regno Unito 71
TR - Turchia 54
RU - Federazione Russa 51
UA - Ucraina 51
PL - Polonia 49
SE - Svezia 35
FI - Finlandia 33
CA - Canada 31
FR - Francia 28
MX - Messico 28
AR - Argentina 26
ID - Indonesia 25
IN - India 23
ZA - Sudafrica 21
NL - Olanda 19
BD - Bangladesh 17
JP - Giappone 14
EC - Ecuador 11
UZ - Uzbekistan 11
AT - Austria 10
CZ - Repubblica Ceca 8
IQ - Iraq 8
PK - Pakistan 8
CO - Colombia 6
PY - Paraguay 6
BE - Belgio 5
ES - Italia 5
PH - Filippine 5
AE - Emirati Arabi Uniti 4
KR - Corea 4
LT - Lituania 4
AU - Australia 3
CL - Cile 3
PE - Perù 3
IL - Israele 2
JM - Giamaica 2
KH - Cambogia 2
LB - Libano 2
MN - Mongolia 2
NP - Nepal 2
PA - Panama 2
PT - Portogallo 2
SY - Repubblica araba siriana 2
TN - Tunisia 2
UY - Uruguay 2
VE - Venezuela 2
AL - Albania 1
AM - Armenia 1
BG - Bulgaria 1
BO - Bolivia 1
BY - Bielorussia 1
CI - Costa d'Avorio 1
CR - Costa Rica 1
CV - Capo Verde 1
DZ - Algeria 1
EG - Egitto 1
ET - Etiopia 1
EU - Europa 1
IE - Irlanda 1
IR - Iran 1
JO - Giordania 1
KE - Kenya 1
KW - Kuwait 1
KZ - Kazakistan 1
MY - Malesia 1
NZ - Nuova Zelanda 1
OM - Oman 1
QA - Qatar 1
RS - Serbia 1
TT - Trinidad e Tobago 1
TV - Tuvalu 1
TW - Taiwan 1
Totale 5.864
Salva come PNG Salva come JPEG
Città #
Dallas 1.011
Singapore 368
Ashburn 326
Santa Clara 196
Hong Kong 186
Beijing 167
Chandler 138
Fairfield 138
Houston 98
Ann Arbor 93
Ferrara 89
Woodbridge 85
Los Angeles 78
Jacksonville 54
Seattle 51
Wilmington 51
Warsaw 48
Ho Chi Minh City 47
Princeton 46
Cambridge 44
Munich 33
Buffalo 31
New York 31
São Paulo 31
Izmir 25
Shanghai 24
Chicago 23
Jakarta 21
Hanoi 19
San Diego 18
London 17
Bologna 15
Brooklyn 15
Mexico City 14
Milan 14
Tokyo 14
Chennai 13
Nanjing 13
Nuremberg 13
Stockholm 13
Turku 13
Washington 12
Redondo Beach 11
Johannesburg 10
Tashkent 10
Toronto 10
Boardman 9
Changsha 9
Falls Church 9
Helsinki 9
Manchester 9
Atlanta 8
Brno 8
Curitiba 8
Orem 8
Poplar 8
Rio de Janeiro 8
Amsterdam 7
Frankfurt am Main 7
Hefei 7
Montreal 7
Phoenix 7
Boston 6
Salvador 6
Belo Horizonte 5
Brasília 5
Brussels 5
Calgary 5
Council Bluffs 5
Denver 5
Guayaquil 5
Hải Dương 5
Osasco 5
Padova 5
Redmond 5
San Francisco 5
Secaucus 5
Assago 4
Asunción 4
Baghdad 4
Charlotte 4
Da Nang 4
Dhaka 4
Ferrara di Monte Baldo 4
Goiânia 4
Haiphong 4
Lahore 4
Las Vegas 4
Manila 4
Molinella 4
Norwalk 4
Pelotas 4
Porto Alegre 4
Ribeirão Preto 4
San Giorgio delle Pertiche 4
São José do Rio Preto 4
São José dos Campos 4
Addison 3
Bauru 3
Campos dos Goytacazes 3
Totale 4.071
Salva come PNG Salva come JPEG
Nome #
[1,2,4]triazolo[1,5-c]pyrimidines as A(3) adenosine receptor antagonists 839
A3 Adenosine Receptors as Modulators of Inflammation: From Medicinal Chemistry to Therapy 235
2-Arylpyrazolo[4,3-d]pyrimidin-7-amino derivatives as new potent and selective human A3 adenosine receptor antagonists. Molecular modeling studies and pharmacological evaluation 226
5,7-Disubstituted-[1,2,4]triazolo[1,5-a][1,3,5]triazines as pharmacological tools to explore the antagonist selectivity profiles toward adenosine receptors 222
Structural refinement of pyrazolo[4,3-d]pyrimidine derivatives to obtain highly potent and selective antagonists for the human A3 adenosine receptor 179
Pyrazolo[4,3-e][1,2,4]triazolo[1,5-c]pyrimidines and Structurally Simplified Analogs. Chemistry and SAR Profile as Adenosine Receptor Antagonists 164
The influence of the 1-(3-Trifluoromethyl-Benzyl)-1H-Pyrazole-4-yl moiety on the adenosine receptors affinity profile of pyrazolo[4,3-e][1,2,4]Triazolo[1,5-c] pyrimidine derivatives 155
7-Amino-2-phenylpyrazolo[4,3-d]pyrimidine derivatives: Structural investigations at the 5-position to target human A(1) and A(2A) adenosine receptors. Molecular modeling and pharmacological studies 149
Novel Aryl Sulfonamide Derivatives as NLRP3 Inflammasome Inhibitors for the Potential Treatment of Cancer 146
A 2a adenosine receptor: Structures, modeling, and medicinal chemistry 119
null 118
Design and synthesis of 1,4,8-triazaspiro[4.5]decan-2-one derivatives as novel mitochondrial permeability transition pore inhibitors 109
A3 adenosine receptor activation mechanisms: molecular dynamics analysis of inactive, active, and fully active states 102
A QM/MM study of the binding of RAPTA ligands to cathepsin B 99
Probing non-peptide agonists binding at the human nociceptin/orphanin FQ receptor: a molecular modelling study 98
Bridging molecular docking to membrane molecular dynamics to investigate GPCR-ligand recognition: The human A2A adenosine receptor as a key study 94
null 90
Near-Complete Response to Osimertinib for Advanced Non-Small-Cell Lung Cancer in a Pretreated Patient Bearing Rare Compound Exon 20 Mutation (S768I + V774M): A Case Report 89
Revisiting a receptor-based pharmacophore hypothesis for human A(2A) adenosine receptor antagonists 84
Probe Confined Dynamic Mapping for G Protein-Coupled Receptor Allosteric Site Prediction 83
A Multi-Angle Approach to Predict Peptide-GPCR Complexes: The N/OFQ-NOP System as a Successful AlphaFold Application Case Study 82
Aquaporin inhibition by gold(III) compounds: New insights 82
Deciphering the Complexity of Ligand-Protein Recognition Pathways Using Supervised Molecular Dynamics (SuMD) Simulations 82
Activation of carboplatin by carbonate: A theoretical investigation 82
DockBench: An Integrated Informatic Platform Bridging the Gap between the Robust Validation of Docking Protocols and Virtual Screening Simulations 82
Advances in Computational Techniques to Study GPCR-Ligand Recognition 78
Activation of carboplatin by chloride ions: a theoretical investigation 77
Bitopic fluorescent antagonists of the A2A adenosine receptor based on pyrazolo[4,3-: E] [1,2,4]triazolo[1,5- c] pyrimidin-5-amine functionalized congeners 73
Understanding allosteric interactions in G protein-coupled receptors using Supervised Molecular Dynamics: A prototype study analysing the human A3 adenosine receptor positive allosteric modulator LUF6000 73
Conjugates between minor groove binders and Zn(II)-tach complexes: Synthesis, characterization, and interaction with plasmid DNA 72
New Trends in Inspecting GPCR-ligand Recognition Process: the Contribution of the Molecular Modeling Section (MMS) at the University of Padova 71
Alternative quality assessment strategy to compare performances of GPCR-ligand docking protocols: the human adenosine A(2A) receptor as a case study 70
Enhancing Ligand and Protein Sampling Using Sequential Monte Carlo 69
Sensitivity of Binding Free Energy Calculations to Initial Protein Crystal Structure 68
Rationalization of the inhibition activity of structurally related organometallic compounds against the drug target cathepsin B by DFT 68
Targeting Aquaporin Function: Potent Inhibition of Aquaglyceroporin-3 by a Gold-Based Compound 64
Demystifying P2Y1 Receptor Ligand Recognition through Docking and Molecular Dynamics Analyses 63
Design and in Vivo Characterization of A 1 Adenosine Receptor Agonists in the Native Ribose and Conformationally Constrained (N)-Methanocarba Series 62
Advances in GPCR modeling evaluated by the GPCR Dock 2013 assessment: Meeting new challenges 61
Synthesis and Spectroscopic Characterisation of a Heterodinuclear Iron(III)-Copper(II) Complex Based on an Asymmetric Dinucleating Ligand System 61
Repurposing of a nucleoside scaffold from adenosine receptor agonists to opioid receptor antagonists 61
South (S)- and north (N)-methanocarba-7-deazaadenosine analogues as inhibitors of human adenosine kinase 60
Structure-Guided Modification of Heterocyclic Antagonists of the P2Y 14 Receptor 59
Pyrimidine nucleotides containing a (S)-methanocarba ring as P2Y6 receptor agonists 57
Structure activity relationship of 2-arylalkynyl-adenine derivatives as human A3 adenosine receptor antagonists 57
Exploring the recognition pathway at the human A2A adenosine receptor of the endogenous agonist adenosine using supervised molecular dynamics simulations 56
Structure-Based Design of 3-(4-Aryl-1H-1,2,3-Triazol-1-yl)-Biphenyl Derivatives as P2Y14 Receptor Antagonists 56
Structure-Based Scaffold Repurposing for G Protein-Coupled Receptors: Transformation of Adenosine Derivatives into 5HT2B/5HT2C Serotonin Receptor Antagonists 55
Purine (N)-Methanocarba Nucleoside Derivatives Lacking an Exocyclic Amine as Selective A3 Adenosine Receptor Agonists 53
Journal of Medicinal Chemistry Collection: Drug Discovery in Italy 52
Supramolecular delivery systems for polyphenols: A green approach to predict in vivo permeability through an in vitro setup 51
Breakthrough in GPCR Crystallography and Its Impact on Computer-Aided Drug Design 51
Perturbation of fluid dynamics properties of water molecules during G protein-coupled receptor-ligand recognition: the human A2A adenosine receptor as a key study 49
Structural probing and molecular modeling of the A3 adenosine receptor: A focus on agonist binding 48
Influence of key amino acid mutation on the active site structure and on folding in acetyl-CoA synthase: A theoretical perspective 48
Enhancing torsional sampling using fully adaptive simulated tempering 48
Implementing the “Best Template Searching” tool into Adenosiland platform 46
Polypharmacology of conformationally locked methanocarba nucleosides 44
In silico 3D modeling of binding activities 42
Hidden GPCR structural transitions addressed by multiple walker supervised molecular dynamics (mwSuMD) 39
The path to the G protein-coupled receptor structural landscape: Major milestones and future directions 35
Protein–Ligand Docking: Virtual Screening and Applications to Drug Discovery 35
HETEROCYCLIC P2Y14 RECEPTOR ANTAGONISTS 31
Inspecting receptor-ligand interaction using molecular dynamics simulations: new insights from Adenosiland 21
P2Y14 Receptor 21
P3.12.20 VAF of EGFR Mutations in Relation to Early Tumor Shrinkage or Deepness of Response During Osimertinib in NSCLC Patients 1
Totale 6.016
Salva come PNG Salva come JPEG
Categoria #
all - tutte 36.000
article - articoli 0
book - libri 0
conference - conferenze 0
curatela - curatele 0
other - altro 0
patent - brevetti 0
selected - selezionate 0
volume - volumi 1.754
Totale 37.754
Salva come PNG Salva come JPEG


Totale Lug Ago Sett Ott Nov Dic Gen Feb Mar Apr Mag Giu
2020/2021159 0 0 0 0 0 24 7 25 16 45 32 10
2021/2022366 2 16 6 100 16 5 18 61 20 7 13 102
2022/2023313 51 22 24 21 40 26 8 44 47 9 13 8
2023/2024271 16 25 27 12 28 48 14 24 7 4 4 62
2024/20251.244 19 21 98 23 137 100 38 64 229 172 183 160
2025/20263.025 394 383 1.139 452 621 36 0 0 0 0 0 0
Totale 6.016